McMahan VM, Kingston S, Newman A, et al.; Interest in reducing meth-amphetamine and opioid use among syringe services program participants in Washington State. Drug Alcohol Depend. 2020;216:108243.
Marlatt GA, Larimer ME, Witkiewitz K, eds. Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors. 2nd ed. Guilford Press; 2012.
Nyblade L, Stockton MA, Giger K, et al.; Stigma in health facilities: why it matters and how we can change it. BMC Med. 2019;17(1):25.
van Boekel LC, Brouwers EPM, van Weeghel J, et al.; Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1–2):23-35.
Van Cappellen P, Rice EL, Catalino LI, et al.; Positive affective processes underlie positive health behaviour change. Psychol Health. 2018;33(1):77-97.
Larney S, Tran LT, Leung J, et al.; All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis. JAMA Psychiatry. 2020;77(5):493-502.
Legislative Analysis and Public Policy Association. Naloxone access: summary of state laws. September 2020. Accessed September 18, 2021. https://legislativeanalysis.org/wp-content/uploads/2020/10/Naloxone-summary-of-state-laws-FINAL-9.25.2020.pdf
Walley AY, Xuan Z, Hackman HH, et al.; Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts. BMJ. 2013;346 : f174.
Irvine MA, Buxton JA, Otterstatter M, et al.; Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada. Lancet Public Health. 2018;3(5):e218-e225.
Bird SM, McAuley A. Scotland's National Naloxone Programme. Lancet. 2019;393(10169):316-318.
Behar E, Rowe C, Santos G-M, et al.; Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain. J Gen Intern Med. 2017;32(3):291-295.
Wakeman SE, Larochelle MR, Ameli O, et al.; Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
The ASAM National Practice Guideline for the treatment of opioid use disorder: 2020 focused update [published correction appears in J Addict Med. 2020;14(3):267].. J Addict Med. 2020;14(2S suppl 1):1-91.
Huhn AS, Hobelmann JG, Strickland JC, et al.; Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States. JAMA Netw Open. 2020;3(2):e1920843.
Sordo L, Barrio G, Bravo MJ, et al.; Mortality risk during and after opioid substitution treatment. BMJ. 2017;357:j1550.
Mattick RP, Breen C, Kimber J, et al.; Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
Zoorob R, Kowalchuk A, de Grubb MM. Buprenorphine therapy for opioid use disorder. Am Fam Physician. 2018;97(5):313-320. Accessed September 15, 2021. https://www.aafp.org/afp/2018/0301/p313.html
Federal Register. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. April 28, 2021. Accessed June 15, 2021. https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphinefor-treating-opioid-use-disorder
Lee JD, Nunes EV, Novo P, et al.; Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT). Lancet. 2018;391(10118):309-318.
Centers for Disease Control and Prevention. Syringe services programs (SSPs) fact sheet. Updated May 23, 2019. Accessed May 11, 2021. https://www.cdc.gov/ssp/syringe-services-programs-factsheet.html
World Health Organization. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users; 2012. Accessed September 18, 2021. https://www.who.int/publications/i/item/978924150437
Platt L, Minozzi S, Reed J, et al.; Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;(9):CD012021.
Marx MA, Crape B, Brookmeyer RS, et al.; Trends in crime and the introduction of a needle exchange program. Am J Public Health. 2000;90(12):1933-1936.
Hagan H, McGough JP, Thiede H, et al.; Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19(3):247-252.
Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374(9):843-852.
Heil SH, Jones HE, Arria A, et al.; Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2011;40(2):199-202.
Terplan M, Hand DJ, Hutchinson M, et al.; Contraceptive use and method choice among women with opioid and other substance use disorders: a systematic review. Prev Med. 2015;80:23-31.
Centers for Disease Control and Prevention. Appendix D. Contraceptive effectiveness. April 25, 2014. Morb Mortal Wkly Rep (MMWR). Accessed April 25, 2021. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6304a5.htm
Committee on Gynecologic Practice Long-Acting Reversible Contraception Working Group; Committee opinion no. 642: Increasing access to contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol. 2015;126(4):e44-e48.